Highest-materiality recent filing
BioNexus begins VitaGuard MRD deployment in Southeast Asia; aims to undercut $3,000 legacy tests
Initial deployments in select Southeast Asian medical hubs during 2026; platform targets under $3,000 per test vs legacy costs often exceeding $3,000.
ARC Group committed to buy up to $500M of BGLC common stock over 36 months at 3.0-3.5% discount to VWAP; 175k commitment shares issued at $4.32.
BGLC enters definitive cross-equity deal for Fidelion's VitaGuard MRD platform in SE Asia
BGLC subscribes for at least 15% of Fidelion shares; issues 19.9% of its common stock to Fidelion.
BioNexus Gene Lab signs non-binding partnership with BirchBioMed for FS2 topical platform in SE Asia
BGLC to lead Birch's $10M financing round; will issue 4.99% of its outstanding common shares to Birch.
BioNexus Gene Lab enters strategic alliance for VitaGuard MRD platform in SE Asia
BGLC to acquire equity stake in Fidelion Diagnostics and exclusive commercial rights to VitaGuard MRD platform across ASEAN.
BioNexus Gene Lab regains Nasdaq minimum bid price compliance, avoids delisting
Received Nasdaq Panel confirmation on Apr 30, 2025, that BGLC met $1.00 minimum bid price rule.
Reverse stock split at 1-for-10 ratio; effective 12:01 a.m. ET on April 7, 2025.
Board approved Ethereum (ETH) as the primary treasury asset; BGLC is first Nasdaq-listed company to do so.
BioNexus Gene Lab creates Series Z Preferred with 5B votes to facilitate Reverse Stock Split
Created one share of Series Z Preferred Stock with 5,000,000,000 votes, solely on Reverse Stock Split matter.
BioNexus Gene Lab gets Nasdaq extension to May 1, 2025 for bid price compliance; plans reverse split
Nasdaq Hearings Panel grants temporary exception until May 1, 2025 to regain minimum $1.00 bid price.
Received delisting notice on Nov 5, 2024 for failing to maintain minimum $1 bid price after two 180-day grace periods ended Nov 4.
Two directors resign from BioNexus Gene Lab board effective immediately
Wei Foong Lim and Koon Wai Wong resigned as directors on October 9, 2024.
BioNexus Gene Lab alleges unlawful proxy solicitation; stock plan and reverse split fail
Three director nominees re-elected despite significant against votes (Su-Leng Tan Lee: 4.1M for vs 6.3M against).
BioNexus Gene Lab subsidiary signs outsourcing deal with Vitarray for mRNA detection in SE Asia
Agreement for mRNA dynamic gene detection services targeting Southeast Asian market.
BioNexus Gene Lab (BGLC) announces MyCIF co-investment in AISB, total round RM 1.7M (~$390k)
Malaysian Securities Commission co-invests alongside BGLC in Ascension Innovation under ESI scheme; total round RM 1.7M (~USD 390k).
BioNexus Gene Lab removes eight directors, appoints four new directors and new CEO
Stockholders owning 50.1% (17,792,663 shares) approved removal of eight directors and appointment of four new directors via written consent.
BioNexus Gene Lab receives Nasdaq bid-price deficiency notice
Closing bid price below $1.00 for 33 consecutive business days (Sept 20 - Nov 3, 2023).
Bionexus Gene Lab appoints Chi Yuen Leong as CEO and director, effective Oct 12, 2023
Chi Yuen Leong appointed CEO and director effective October 12, 2023; annual compensation $24,000.
Bionexus Gene Lab CEO Sook Keng Yeoh resigns effective Oct 4; no successor named yet
CEO Sook Keng Yeoh resigned as CEO and director on October 4, 2023.
BioNexus closes $5.75M public offering and uplists to Nasdaq
Closed underwritten public offering of 1,437,500 shares at $4.00/share; gross proceeds $5.75M.
Bionexus Gene Lab replaces Chairman, CEO, and President in leadership reshuffle
Chairman Soo Kow Lai, CEO Chan Chong Wong, and President Chi Yuen Leong resigned effective Aug 12, 2022; no disagreement cited.
Concurrent with the new appointment, Mr. Su-Leng Tan Lee ceased his role as acting Chief Financial Officer and Principal Financial Officer of the Company.
On June 17, 2025, the Board of Directors of BioNexus Gene Lab Corp. (the “Company”) appointed Ms. Chong Set Fui (Angeline) as the Company’s Chief Financial Officer and Principal Financial Officer, effective immediately.
Additionally, the Board has re-appointed Mr. Su-Leng Tan Lee as Secretary of the Company and has appointed him as President, effective immediately.
On November 5, 2024, the Board of Directors of the Company appointed Ms. Jook Yuen Low as an independent director to the Board, effective immediately.
On October 9, 2024, Mr. Wei Foong Lim and Mr. Koon Wai Wong resigned in their capacities as members of the Board of Directors of the Company, effective immediately.
On October 9, 2024, Mr. Wei Foong Lim and Mr. Koon Wai Wong resigned in their capacities as members of the Board of Directors of the Company, effective immediately.
On October 30, 2023, Ms. Wei Li Leong, the Chief Financial Officer (“CFO”), tendered her resignation letter to BioNexus Gene Lab Corp. (the “Company”) from her position at the Company.
On October 12, 2023, the board of directors of the Bionexus Gene Lab Corp. (“the Company”) approved the appointment of Mr. Chi Yuen Leong as the Chief Executive Officer and a director, effective October 12, 2023.
On October 12, 2023, the board of directors of the Bionexus Gene Lab Corp. (“the Company”) approved the appointment of Mr. Chi Yuen Leong as the Chief Executive Officer and a director, effective October 12, 2023.
On October 4, 2023, Mr. Sook Keng Yeoh, the Chief Executive Officer and a member of the Board of Directors, tendered his resignation letter to Bionexus Gene Lab Corp. (the “Company”) from his positions at the Company.
The Company and Mr. Liong Tai Tan agreed that the resignations would be effective August 31, 2023.
the Board of Directors of the Company approved the appointment of Mr. Lee Su-Leng Tan as the Chief Operating Officer and not a director, effective September 1, 2023.
Max materiality 0.85 · Median 0.57 · Most common event other_material